Hsbc Holdings PLC Has $190,000 Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Hsbc Holdings PLC lowered its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 70.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,577 shares of the company’s stock after selling 29,986 shares during the period. Hsbc Holdings PLC’s holdings in iTeos Therapeutics were worth $190,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Los Angeles Capital Management LLC acquired a new stake in iTeos Therapeutics during the first quarter valued at $401,000. China Universal Asset Management Co. Ltd. increased its holdings in iTeos Therapeutics by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock worth $94,000 after buying an additional 2,737 shares during the last quarter. Vanguard Group Inc. raised its position in iTeos Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after acquiring an additional 9,660 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in iTeos Therapeutics in the first quarter valued at approximately $3,337,000. Finally, Public Employees Retirement System of Ohio grew its position in iTeos Therapeutics by 4.9% in the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after acquiring an additional 1,817 shares in the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Wedbush reiterated an “outperform” rating and set a $21.00 price target on shares of iTeos Therapeutics in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research note on Monday, September 16th. Finally, Wells Fargo & Company assumed coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price for the company.

iTeos Therapeutics Price Performance

ITOS stock opened at $10.02 on Friday. The stock has a market capitalization of $361.95 million, a price-to-earnings ratio of -2.65 and a beta of 1.36. The company has a 50-day moving average of $14.62 and a two-hundred day moving average of $14.55. iTeos Therapeutics, Inc. has a 52-week low of $8.20 and a 52-week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.86. The business had revenue of $35.00 million for the quarter, compared to the consensus estimate of $4.20 million. Equities analysts expect that iTeos Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.